ATE214939T1 - Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung - Google Patents

Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung

Info

Publication number
ATE214939T1
ATE214939T1 AT92922537T AT92922537T ATE214939T1 AT E214939 T1 ATE214939 T1 AT E214939T1 AT 92922537 T AT92922537 T AT 92922537T AT 92922537 T AT92922537 T AT 92922537T AT E214939 T1 ATE214939 T1 AT E214939T1
Authority
AT
Austria
Prior art keywords
interleukin
treatment
pct
inhibiting compound
neurological conditions
Prior art date
Application number
AT92922537T
Other languages
English (en)
Inventor
Nancy Jane Rothwell
Gareth Roberts
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919123161A external-priority patent/GB9123161D0/en
Priority claimed from GB919125670A external-priority patent/GB9125670D0/en
Application filed by Univ Manchester filed Critical Univ Manchester
Application granted granted Critical
Publication of ATE214939T1 publication Critical patent/ATE214939T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92922537T 1991-10-31 1992-11-02 Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung ATE214939T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919123161A GB9123161D0 (en) 1991-10-31 1991-10-31 Treatment of neurological conditions
GB919125670A GB9125670D0 (en) 1991-11-30 1991-11-30 Treatment of neurogical conditions
PCT/GB1992/002023 WO1993008820A1 (en) 1991-10-31 1992-11-02 Treatment of neurological conditions by an interleukin-1 inhibiting compound

Publications (1)

Publication Number Publication Date
ATE214939T1 true ATE214939T1 (de) 2002-04-15

Family

ID=26299779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922537T ATE214939T1 (de) 1991-10-31 1992-11-02 Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung

Country Status (10)

Country Link
US (1) US6090775A (de)
EP (1) EP0610336B1 (de)
JP (1) JP3623501B2 (de)
AT (1) ATE214939T1 (de)
AU (3) AU2884592A (de)
CA (1) CA2122596C (de)
DE (1) DE69232516T2 (de)
DK (1) DK0610336T3 (de)
ES (1) ES2173871T3 (de)
WO (2) WO1993008820A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5843969A (en) * 1995-04-07 1998-12-01 Teijin Limited Protecting agent for organ or tissue
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US20030040660A1 (en) * 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
WO2003022213A2 (en) * 2001-09-06 2003-03-20 Board Of Regents, The University Of Texas System Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
JP2009517069A (ja) * 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン1受容体1型に結合する競合ドメイン抗体フォーマット
EP2385839B1 (de) * 2009-01-09 2014-11-26 The Schepens Eye Research Institute, Inc. Therapeutische zusammensetzungen zur behandlung von hornhauterkrankungen
RU2425642C1 (ru) * 2009-12-14 2011-08-10 Государственное образовательное учреждение дополнительного профессионального образования "Иркутский государственный институт усовершенствования врачей Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития постинсультной деменции
HRP20230776T1 (hr) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ, インコーポレイテッド 眼送達のためのキメラサイトカイン製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106861A (en) * 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
AU5921890A (en) * 1989-06-13 1991-01-08 Smithkline Beecham Corporation Monokine activity interference
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases

Also Published As

Publication number Publication date
AU7648296A (en) 1997-02-13
DK0610336T3 (da) 2002-07-22
EP0610336A1 (de) 1994-08-17
CA2122596C (en) 2008-06-03
WO1993008820A1 (en) 1993-05-13
ES2173871T3 (es) 2002-11-01
AU2884592A (en) 1993-06-07
JP3623501B2 (ja) 2005-02-23
US6090775A (en) 2000-07-18
EP0610336B1 (de) 2002-03-27
AU2804192A (en) 1993-06-07
WO1993008819A1 (en) 1993-05-13
JPH07505608A (ja) 1995-06-22
DE69232516T2 (de) 2002-10-31
CA2122596A1 (en) 1993-05-13
DE69232516D1 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DE69232516D1 (de) Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
DE69934698D1 (de) Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
NO954275D0 (no) Risperidonpamoat
DE59400489D1 (de) Fungizide Wirkstoffkombinationen
KR950010890A (ko) 폐경기 증후군의 치료방법
MX9203775A (es) Compuestos arilicos biciclicos substituidos, que exhiben actividad antagonista al leucotrieno b4 selectiva.
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
KR910004191A (ko) 신질환치료제
FR2690847B1 (fr) Compositions a activite agoniste des recepteurs analogues a 5ht1 selective.
ITMI920955A1 (it) Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili
ATE185071T1 (de) Steroide enthaltende zusammensetzungen zur anwendung am auge und ihre verwendung zur behandlung des glaukoms
BR0206262A (pt) Composição antimicrobiana lìquida, uso da mesma, e, método de exterminar ou eliminar vìrus ou esporos
MX9304075A (es) Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
ATE141248T1 (de) Neue bis-phenyl-hexene
ES2144452T3 (es) Medicamento para el tratamiento de infecciones protozoarias provocadas por babesia.
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
NO921525D0 (no) L-alfa-glyserofosforyl-d-myo-inositol for behandling av perifere nervelidelser og hjernelidelser
EP0645963A4 (de)
EP0505389A4 (en) Antiparasitic composition for animal use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee